CDC Advisory Committee Recommends PCV13 for Older Adults in US
4 September 2014: Pfizer globally announced that the Centre for Disease Control & Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend PCV 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein] for routine use to help protect adults aged 65 years and older against pneumococcal disease, which includes pneumonia caused by the 13 pneumococcal serotypes included in the vaccine. The ACIP specifically voted to recommend the following:
- Adults 65 years of age or older who have not previously received pneumococcal vaccine or whose previous vaccination history is unknown should receive a dose of PCV13 first, followed by a dose of PPV.
- Adults 65 years of age or older who have not previously received PCV13 and who have previously received one or more doses of PPV should receive a dose of PCV13
- The recommendations for routine PCV13 use among adults 65 years and older* should be re-evaluated in 2018 and revised as needed (*if approved by ACIP and CDC Director)
The recommendations, including the time intervals between vaccines, will be forwarded to the director of the CDC and the U.S. Department of Health and Human Services for review and approval; once approved, the recommendations are published in the Morbidity and Mortality Weekly Report.
“Among adults aged 65 and above, PCV13 plays a vital role in reducing the risk factors for vaccine-type pneumococcal community-acquired pneumonia and invasive pneumococcal disease. Vaccine is advantageous for older population of Pakistan who are highly susceptible for pneumococcal diseases,”
said by Prof. Sajid Maqbool, leading pediatricians and infectious disease expert.
“PCV 13 has set milestones in the field of vaccines worldwide. Alongside children, PCV13 has made its mark among adults. Pfizer remains committed to working with the healthcare and public health communities to raise awareness of the importance of adult immunization among consumers”
- said by Dr. Farid Khan, Country manager Pfizer Pakistan.
About Pneumococcal Disease
Pneumococcal disease refers to a group of illnesses caused by Streptococcus pneumonia bacteria. Invasive pneumococcal disease occurs when bacteria enter the bloodstream or another site that is normally sterile. Non-invasive pneumococcal pneumonia occurs when the bacteria cause infection in the lungs but are not detected in the blood concurrently. In adults, pneumonia is the most common presentation of pneumococcal disease. For every one case of invasive pneumococcal pneumonia in adults, it is estimated that at least three cases of non-invasive pneumococcal pneumonia occur. While non-invasive forms of pneumococcal disease are typically more common, the invasive types of disease are generally more severe.
Pfizer Inc: Working together for a healthier world™
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com